Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash from Investing Activities: 2020-2021

Historic Cash from Investing Activities for Design Therapeutics (DSGN) over the last 2 years, with Dec 2021 value amounting to -$50.1 million.

  • Design Therapeutics' Cash from Investing Activities fell 2605.46% to -$50.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$53.6 million, marking a year-over-year decrease of 59.84%. This contributed to the annual value of $44.0 million for FY2024, which is 16.33% down from last year.
  • As of Q4 2021, Design Therapeutics' Cash from Investing Activities stood at -$50.1 million, which was down 892.84% from -$5.0 million recorded in Q3 2021.
  • In the past 5 years, Design Therapeutics' Cash from Investing Activities ranged from a high of $23.0 million in Q1 2021 and a low of -$50.1 million during Q4 2021.
  • In the last 2 years, Design Therapeutics' Cash from Investing Activities had a median value of -$2.3 million in 2020 and averaged -$10.9 million.
  • Data for Design Therapeutics' Cash from Investing Activities shows a peak YoY increase of 158.67% (in 2021) and a maximum YoY decrease of 4,405.59% (in 2021) over the last 5 years.
  • Design Therapeutics' Cash from Investing Activities (Quarterly) stood at $2.0 million in 2020, then plummeted by 2,605.46% to -$50.1 million in 2021.
  • Its last three reported values are -$50.1 million in Q4 2021, -$5.0 million for Q3 2021, and -$21.6 million during Q2 2021.